Shots: Aduro to receive $12M upfront, up to $620M milestones and royalties on sales from Lilly. Lilly to get rights for Aduro’s cGAS-STING pathway inhibitor program and will be responsible for all costs […]readmore
Tags : Eli Lilly
Shots: The FDA’s designation is based on P-II study results assessing Baricitinib in patients with SLE, presented at European Congress of Rheumatology 2018 Lilly is also evaluating baricitinib’s two doses in […]readmore
Shots: NextCure to get $25M upfront plus milestones & royalty payments in addition to $15M equity investments. NextCure & Lilly will hold equal rights to exclusively license the Abs The […]readmore
Shots: The EMPRISE study involves assessing of Jardiance vs DPP-4 inhibitors in ~35,000 people with T2D initiated from 2014 to 2019, demonstrated 44% reduction in relative risk of hospitalization […]readmore
Shots: Real Time Evidence resulted in 9/10 responders experiencing anxiety (61%), insomnia (56%) and depression (56%), also affects their family and friends with anxiety (59%) and depression (45%). The reports […]readmore
Regulatory
Eli Lilly’s Olumiant (baricitinib) Receives FDA Approval for Moderately-to-Severely Active
Shots: The approval is based on P-III RA-BEACON study results assessing Olumiant vs PBO in 527 patients with inadequate response or intolerance to one or more TNF inhibitor therapies P-III […]readmore